Equity Overview
Price & Market Data
Price: $1.50
Daily Change: $0.00 / 0.00%
Range: $1.45 - $1.50
Market Cap: $473,145,184
Volume: 701
Performance Metrics
1 Week: 12.77%
1 Month: 2.58%
3 Months: -9.14%
6 Months: -54.31%
1 Year: -54.70%
YTD: -38.73%
Details
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company's products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults. The company was incorporated in 2010 and is based in Sydney, Australia.